New insider activity at Zimmer Biomet Holdings ( (ZBH) ) has taken place on June 13, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sang Yi, Group President of Asia Pacific, has recently sold 1,000 shares of Zimmer Biomet Holdings stock, amounting to a total transaction value of $95,000.
Recent Updates on ZBH stock
In the last 24 hours, Zimmer Biomet Holdings has experienced notable developments impacting its stock. Treace Medical has filed a patent infringement suit against the company, which could potentially affect its legal and financial standing. Additionally, Zimmer Biomet has made organizational changes by appointing Kevin Thornal as Group President and approving amendments at its annual meeting, indicating strategic shifts within the company. These changes, along with ongoing market challenges, have contributed to a hold rating from analysts. Furthermore, Canaccord has lowered the price target for Zimmer Biomet from $115 to $101, citing these organizational changes and market conditions as key factors influencing their decision.
Spark’s Take on ZBH Stock
According to Spark, TipRanks’ AI Analyst, ZBH is a Outperform.
Zimmer Biomet’s solid financial performance is a key strength, supported by strategic cash flow management and stable leverage. However, technical indicators point to bearish momentum, and valuation metrics suggest moderate investment appeal. The newly appointed executive leadership could provide future growth opportunities, balancing the current challenges from tariffs and lowered EPS guidance.
To see Spark’s full report on ZBH stock, click here.
More about Zimmer Biomet Holdings
YTD Price Performance: -11.52%
Average Trading Volume: 2,272,972
Technical Sentiment Signal: Sell
Current Market Cap: $18.65B